Stoke Therapeutics (STOK) Operating Expenses (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Operating Expenses of $59.6 million for Q1 2026, up 26.03% year-over-year from $47.3 million in Q1 2025, and down 72.28% quarter-over-quarter from $215.2 million in Q4 2025.
Stoke Therapeutics (STOK) Operating Expenses (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $59.6 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 26.03% year-over-year to $59.6 million; the TTM figure through Mar 2026 stood at $324.8 million (up 184.39% YoY), while the FY2025 annual figure was $205.0 million, up 48.64% from the prior year.
- Operating Expenses for Q1 2026 stood at $59.6 million, down from $215.2 million in the prior quarter.
- The five-year high for Operating Expenses was $215.2 million in Q4 2025, with the low at -$101.2 million in Q4 2023.
- The 5-year median for Operating Expenses is $30.5 million (2023), against an average of $34.0 million.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses tumbled 432.54% in 2023, then soared 1603.58% in 2025.
- Stoke Therapeutics' Operating Expenses stood at $30.4 million in 2022, then sank by 432.54% to -$101.2 million in 2023, then jumped by 135.82% to $36.3 million in 2024, then soared by 493.4% to $215.2 million in 2025, then plunged by 72.28% to $59.6 million in 2026.
- Business Quant data shows STOK's Operating Expenses at $59.6 million in Q1 2026, $215.2 million in Q4 2025, and $53.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 74.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.75 Mn |
| Mar 31, 2026 | 59.65 Mn |
| Dec 31, 2025 | 215.21 Mn |
| Sep 30, 2025 | 53.72 Mn |
| Jun 30, 2025 | -3.82 Mn |
| Mar 31, 2025 | 47.33 Mn |
| Dec 31, 2024 | 36.27 Mn |
| Sep 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | 34.17 Mn |
| Mar 31, 2024 | 32.59 Mn |
| Dec 31, 2023 | -101.24 Mn |
| Sep 30, 2023 | 30.54 Mn |
| Jun 30, 2023 | 30.78 Mn |
| Mar 31, 2023 | 29.84 Mn |
| Dec 31, 2022 | 30.44 Mn |
| Sep 30, 2022 | 30.05 Mn |
| Jun 30, 2022 | 28.47 Mn |
| Mar 31, 2022 | 27.80 Mn |
| Dec 31, 2021 | 24.53 Mn |
| Sep 30, 2021 | 22.68 Mn |